This paper reviews the role of beta-blockers in the prevention of cardiovascular morbidity and mortality in patients with diabetes mellitus. There is good evidence from randomized controlled trials that beta-blockers, in particular the lipophilic agents, substantially reduce cardiovascular mortality and morbidity. However, hitherto beta-blockers have been underused in diabetic patients, perhaps because of perceived risks of beta-blocker therapy. Reappraisal of the evidence suggests that the traditional reluctance to use beta-blockers in this group is based on fears of adverse effects that are largely unfounded.

Type

Journal article

Journal

J Clin Pharm Ther

Publication Date

08/2002

Volume

27

Pages

233 - 242

Keywords

Adrenergic beta-Antagonists, Coronary Disease, Death, Sudden, Cardiac, Diabetes Complications, Humans, Practice Patterns, Physicians', Prospective Studies